Uncategorized
Predictive Oncology’s (NASDAQ: POAI) Board of Directors has announced that it will cancel the Special Meeting of Stockholders that was scheduled for today. Originally scheduled for Dec. 1, 2020, the meeting was adjourned on that date and rescheduled for Dec. 30 because a quorum had not been reached. As of the rescheduled date, the required quorum had still not been reached, with only 47% of the outstanding shares having been voted. In cancelling the meeting, the Board of Directors for POAI, a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, noted that it was not practical to incur the cost of continuing to adjourn the meeting to solicit proxies, because approval of the reincorporation proposal would require not just a majority of the shares voted but the affirmative vote of a majority of the company’s outstanding shares. The board observed that nearly 88% of the shares that had been voted at the special meeting were in support of the proposed reincorporation of the company from Delaware to Nevada; the reason for that proposal is, in part, because of Delaware’s steep franchise taxes. The board will continue to pursue stockholder approval for reincorporation.
To view the full press release, visit http://ibn.fm/kyNgN
About Predictive Oncology Inc.
Predictive Oncology operates through three segments (Skyline, Helomics and Soluble Biotech), which contain four subsidiaries: Helomics, TumorGenesis, Skyline Medical and Soluble Biotech. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. TumorGenesis Inc. specializes in media that help cancer cells grow and retain their DNA/RNA and proteomic signatures, providing researchers with a tool to expand and study cancer cell types found in tumors of the blood and organ systems of all mammals, including humans. Skyline Medical markets its patented and FDA-cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. Soluble Biotech is a provider of soluble and stable formulations for proteins including vaccines, antibodies, large and small proteins and protein complexes. For more information about the company, please visit www.Predictive-Oncology.com.
NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Net Element (NASDAQ: NETE) is a financial technology company in the process of transforming its business model to become a pure-play electric vehicle (“EV”) manufacturer through a pending merger with privately held Mullen Technologies Inc. Mullen recently executed a nonbinding Letter of Intent (“LOI”) with Unlimited Electrical Contractors Corp (“UEC”), a premiere electrical contractor based in Pompano Beach, Florida. The LOI outlines agreements for the purchase of up to 10,000 of Mullen’s MX-05 electric vehicles (“EVs”), with an initial purchase order of 1,500 MX-05s, valued at an estimated $75 million. The LOI states that UEC may order an additional 8,500 vehicles by 2025. UEC is working toward being the first electrical contractor with an all-electric service fleet. The agreement is for a modified variant of the MX-05, an electric crossover SUV based on a skateboard EV platform and a unibody frame available in either a single or dual electric motor configuration. “We’re very excited to work with UEC and are very fortunate that they see the value in Mullen and the MX-05 for their business,” said Mullen Technologies CEO and Chairman David Michery in the press release. “UEC’s order is the first of many commercial fleet relationships we are currently working on. The skateboard platform and low center of gravity of the MX-05 allows us to easily configure the vehicle for many different types of commercial trade use.”
To view the full press release, visit http://ibn.fm/JcWex
About Net Element Inc.
Net Element operates a payments-as-a-service transactional and value-added services platform for small to medium enterprise (“SME”) in the United States and selected emerging markets. On Aug. 5, 2020, Net Element announced the execution of a definitive agreement to merge with privately held Mullen Technologies Inc., a Southern California-based electric vehicle company in a stock-for-stock reverse merger in which Mullen’s stockholders will receive a majority of the outstanding stock in the post-merger company (the “contemplated merger”). The contemplated merger is subject to customary closing conditions, regulatory approvals and shareholder approval for both companies. For additional information, visit www.NetElement.com.
NOTE TO INVESTORS: The latest news and updates relating to NETE are available in the company’s newsroom at http://ibn.fm/NETE
About Green Car Stocks
Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.
To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)
For more information, please visit https://www.GreenCarStocks.com
Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer
Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com
Green Car Stocks is part of the InvestorBrandNetwork.
ABB is a technology firm focused on achieving a productive and sustainable future. Its automation solutions and electrification knowledge have been utilized in a futuristic project that aims to increase productivity by 50% while generating no carbon dioxide emissions.
The global tech company has provided connected operations and control-management systems as well as mobile-operator workplaces with high visualization as part and parcel of a worldwide mining partnership to reduce the climate impact.
The project, referred to as the Sustainable Underground Mining, was designed by LKAB. The aim of the project is to set a new sustainable mining world standard in collaboration with Epiroc, ABB, Combitech and Sandvik. LKAB’s key business is the mining and processing of iron ore and for the steel industry.
The framework outlines the project’s objectives for deeper mining, zero carbon dioxide emissions, productivity growth and safe mines for individuals.
In addition to its partnership with LKAB, ABB will continue its knowledge contributions with regard to automation and workplaces. The partnership’s goal is to discover smarter solutions and alternative methods for mining in the future. A virtual test mine and test work in Northern Sweden’s Kiruna mine will be used to study the best way to establish an autonomous production system that is carbon dioxide free.
The Konsuln orebody is used to show workplaces in the future in an environment that is decentralized and that uses autonomous electric mobile transport systems efficiently. Additionally, the organizations involved will be provided with real-time process information.
ABB is comprised of a big team willing to commit a significant amount of time to the project. The firm includes experts in research and digitalization as well as in automation and electrification. The ABB automation and electrification solutions will have been installed fully by 2022. The goal is that a new mining production standard will be established worldwide by the year 2030.
New technology will be designed and tested in a real mining environment in the Sustainable Underground Mining project to ensure that the natural resource industry in Sweden can grow and generate employment opportunities while remaining competitive both nationally and locally. In the future, digitalized and autonomous machines and mine experts and professionals will work together.
For the project to be implemented, partners and a significant investment on a national scale will be needed. The partners are now seeking collaborations with universities, the Swedish state and research institutes as well as additional suppliers.
Meanwhile, mining firms are continuing their operations amid the pandemic in the most safe and effective ways possible. For instance, Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) has a globally outstanding portfolio of uranium production.
NOTE TO INVESTORS: The latest news and updates relating to Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) are available in the company’s newsroom at http://ibn.fm/UUUU
About MiningNewsWire
MiningNewsWire (MNW) is a specialized communications platform focused on developments and opportunities in the global resources sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, MNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MNW brings its clients unparalleled visibility, recognition and brand awareness. MNW is where news, content and information converge.
To receive SMS text alerts from MiningNewsWire, text “BigHole” to 21000 (U.S. Mobile Phones Only)
For more information, please visit https://www.MiningNewsWire.com
Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.MiningNewsWire.com/Disclaimer
MiningNewsWire
Los Angeles, California
www.MiningNewsWire.com
310.299.1717 Office
Editor@MiningNewsWire.com
MiningNewsWire is part of the InvestorBrandNetwork.
Last week, the Supreme Court of New Hampshire overturned an earlier conviction of a resident from the North Country, whose charges of psilocybin mushroom possession were filed in 2018. The court ruled that the earlier conviction conflicted with the religion the defendant practices, which is Native American based.
The sitting justices stated in a unanimous ruling that as compared to protections in the U.S. constitution, the right of religion in the New Hampshire constitution was stronger. Under the U.S. constitution, sterner balancing tests are required in the event that the illegal drugs in question are used for religious practices.
The Coos County Superior Court’s decision stated that Jeremy D. Mack had practiced an earth-based religion for years and had become a member of a branch of the Oklevueha Native American Church known as the Oratory of Mystical Sacraments. After joining the church, the resident of Colebrook was provided with a membership card, which permitted him to consume psilocybin mushrooms sacramentally.
The church had limitations that applied to the ingestion of the sacrament, stating that the sacrament was not to be taken around children, when shooting firearms, in public or when driving. Instead, the church strongly recommended that the sacrament be consumed in seclusion.
Mack had been found guilty of possession of psilocybin in 2018 after state police found the hallucinogenic mushrooms during a search for weapons under a confiscation order that involved a different civil case.
Psilocybin has been classified as a Schedule 1 drug by the federal government. This means that the hallucinogenic drug is not allowed to be used in a medical setting and has a high potential for abuse. Other drugs that have been classified in this category include LSD, marijuana and heroin.
The four justices stated that the trial judge who presided over the trial that ultimately led to the conviction of Mack made a mistake in the legal rulings. Echoing an 1868 opinion, one of the justices, Supreme Court Justice James Bassett, stated that in Part I, Article 5, there existed a universal declaration and statement that cited that every individual has the unalienable and natural right to belong to the religion persuasion of his choice, to worship God publicly and privately in the season and manner that is most agreeable to the individual, dictated by reason and his own conscience.
He then added that the Constitution of New Hampshire protected both practices and beliefs while the U.S. constitution protected religious beliefs.
Still on the matter if psychedelic substances, a number of companies are focused on leveraging the emerging opportunities in this sector. For instance, Cybin Inc. (NEO: CYBN), a Canadian-based firm, has two divisions (Natures Journey Inc. and Serenity Life Sciences), each of which is focused on therapeutic nutraceutical and medicinal psychedelic products respectively.
NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) are available in the company’s newsroom at https://ibn.fm/CYBN
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.
Creatd (NASDAQ: CRTD), the parent company of Vocal, today announced its entry into definitive securities purchase agreements in connection with a private placement of its Series E Convertible Preferred Stock (the “Preferred Stock”) and warrants to existing shareholders as well as new institutional investors. Upon the closing of the financing, expected to occur on or prior to Jan. 4, 2021, Creatd expects to receive approximately $7.77 million in gross proceeds, not including any proceeds that may be received upon exercise of the warrants. The company intends to use the net proceeds of the financing to satisfy Nasdaq’s stockholders’ equity listing requirements as well as to further accelerate its business plan, social media and digital marketing initiatives, pay non-commission financing expenses, repay all of its minimal remaining outstanding debt, and fund any additional working capital needs and accretive acquisitions.
To view the full press release, visit https://ibn.fm/xcYfw
About Creatd Inc.
Creatd empowers creators, brands and entrepreneurs through technology and partnership. Its flagship technology, Vocal, is a best-in-class creator platform. For more information about Creatd and its Vocal platform, visit www.Creatd.com and www.Vocal.media.
NOTE TO INVESTORS: The latest news and updates relating to CRTD are available in the company’s newsroom at http://ibn.fm/CRTD
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
TORONTO, Dec. 30, 2020 — RAMM Pharma Corp. (including its wholly owned subsidiaries, the “Company” or “RAMM”) (CSE: RAMM), a leader in plant-derived cannabinoid pharmaceutical and other cannabis-based products, is pleased to announce that the Company has acquired 49% of Canapar Corp. (“Canapar”) (the “Canapar Shares”). The Canapar Shares were acquired from Canopy Rivers Corporation (“Canopy Rivers”), a wholly owned subsidiary of Canopy Rivers Inc. (TSX: RIV) (OTC: CNPOF). Canapar, through its wholly owned subsidiary Canapar SrL (“Canapar Italy”), will be one of Europe’s largest vertically integrated Cannabis companies when fully operational. Canapar’s state of the art extraction plant is the largest in Europe and has been custom designed for the production of active compounds to be used in high-quality pharmaceutical, wellness and cosmetic products from its 1,000-hectare Italian-based organic hemp production and processing platform. The strategic investment is expected to immediately enhance RAMM and Canapar’s ability to capitalize on the rapidly expanding European and global cannabis markets, provide additional opportunities to expand RAMM’s distribution footprint for its portfolio of internationally registered and approved pharmaceutical and other cannabis-based products and further leverage Canapar’s significant investment in its extensive vertically integrated operation and industry expertise.
“Canapar is positioned to be a leader in the European Cannabis market and this strategic investment provides RAMM with a significant presence in Europe creating a prominent and differentiated global platform,” stated Jack Burnett, Chief Executive Officer of RAMM.
“We welcome RAMM as a strategic investor in Canapar and are very optimistic about the opportunities to cross-leverage our respective expertise, product portfolios and established presence in an expansive number of international markets”, stated Sergio Martines, Chief Executive Officer of Canapar.
A video overview of Canapar’s operations can be found he r e and additional information about Canapar and can be found on its website www.canapar.com .
About the European Cannabis Market
Europe represents one of the largest potential cannabis markets globally. The Europe cannabis market is currently valued at US$3.5 billion and expected to reach US$37 billion by 2027 with an anticipated CAGR of 29.6% from 2020 to 2027 (ResearchAndMarkets.com, 2020). European countries are experiencing a transformation in the regulations for marketing cannabis and related products, facilitating easier cultivation, processing, and trade of the cannabis-derived products across this region.
Terms of the Transaction
The Canapar Shares were acquired for C$7,000,000 pursuant to the terms of a share purchase agreement (the “Agreement”) and represent approximately 49% of the issued and outstanding shares of Canapar on a non-diluted basis. Canopy Rivers is also entitled to additional contingent consideration of C$2,000,000 payable in cash or issuable in common shares of RAMM, at the sole discretion of RAMM, on the achievement of certain production milestones at Canapar Italy’s production facility in Sicily. In accordance with the terms of the Agreement, RAMM was also assigned Canopy Rivers’ rights under an investor rights agreement which includes: (i) the right to designate one nominee to Canapar’s current three person board of directors (or two nominees if the size of the board increases to six persons or more); (ii) the right of Ramm to maintain its pro rata ownership percentage of Canapar in connection with future financings; and (iii) a call option providing RAMM with the right to purchase 100% of Canapar’s interest in its investees companies for the greater value of C$200,000,000 or eight times EBITDA.
About Canapar Corp.
Canapar with its wholly owned subsidiaries in Europe is an Italy-based manufacturer and processor of CBD oil and isolates, which are increasingly used as an input into new commercial products in the health and wellness industries. Canapar has secured more than 1,000 hectares of hemp through its outsource farming model and entered into an academic partnership with the University of Catania’s Department of Agriculture. Canapar is also advancing its CBD extraction and processing capabilities through its new facility and is expecting to transform 600 metric tons of hemp biomass annually into CBD isolates and derivative products for distribution in Europe following the commissioning of its extraction machinery. With demand for products that contain natural active ingredients derived from plant extracts increasing significantly, Canapar plans on developing CBD-infused cosmetics, skincare, and beauty products for the Italian cosmetics market, which is the fourth largest such market in Europe, as well as the global market, which provides strong demand for “Made in Italy” brands.
About RAMM Pharma Corp.
Led by renowned cannabis industry experts and backed by successful pioneers in the cannabis sector, RAMM is a leader in the field of cannabinoid pharmacology and product formulation for cannabis-based pharmaceuticals and other cannabis-based products. Founded in 1988 in Montevideo, Uruguay, the Company is a well established pharmaceutical and medical product business that has developed medically registered and approved plant-derived cannabinoid pharmaceutical products. The Company currently has multiple approved and registered products that have been authorized for sale in Uruguay and compassionate use in several Latin American countries, as well as a pipeline of new products in various stages of approval and development produced in the Company’s state of the art Good Manufacturing Practice (GMP) certified cannabis formulation facility. Further to its industry leading activities in the cannabis sector, the Company operates a successful pharmaceutical, cosmetic and nutraceutical product development and medical services business which has been servicing the local market for 30 years.
RAMM Pharma Corp. includes wholly owned subsidiaries Medic Plast SA, Yurelan SA, Glediser SA and Ramm Pharma Holdings Corp.
Additional information about the Company is available at www.rammpharma.com .
For further information, please contact:
Jack Burnett
Chief Executive Officer
+598 2513 9958
info@rammpharma.com
Cautionary Note Regarding Forward-Looking Information
This news release contains “forward-looking information” and “forward-looking statements” (collectively, ” forward looking statements “) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward looking statements relate, among other things, the Company’s strategies and objectives, and future expansion plans.
These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: the anticipated benefits of the acquisition of the Canapar Shares to the Company and its shareholders; the future growth potential of the Company on a post-acquisition basis ; commissioning of Canapar Italy’s extraction machines; efficacy of the Company’s product offerings; the expected timelines associated with the production, roll-out and availability of the Company’s products; the ability to meet increased demand for the Company’s products, changes in prices of required commodities; the impact of COVID-19 on the Company’s workforce, suppliers, partners, customers, and other essential resources and what effect those impacts, if they occur, would have on the Company’s business and operations; future growth potential of the Company; fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the Uruguayan, Latin American, European and international medical and recreational cannabis markets and changing consumer habits; the ability of the Company to successfully achieve its business objectives; plans for expansion; political and social uncertainties; inability to obtain adequate insurance to cover risks and hazards; and the presence of laws and regulations that may impose restrictions on cultivation, production, distribution and sale of cannabis and cannabis related products in Uruguay or internationally; and employee relations. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.
- The COVID-19 pandemic has sickened more than 78 million people worldwide, leading to the deaths of more than 1.7 million people
- The pandemic has hammered businesses as society has attempted to lessen human contact in order to limit the spread of the virus responsible for the illnesses, especially as a growing number of employees of the stressed companies have needed sick leave
- Autonomous Security Robot (“ASR”) developer Knightscope has enhanced its artificial intelligence-equipped sentries with elevated body temperature detection to help companies measure body temperatures of employees and visitors entering their facilities
- The feature will help client companies protect their employees from virus transmission on their premises, potentially reducing liability concerns in the process
As vaccines to combat the novel coronavirus begin to rollout across the country, Americans are acknowledging that it may take weeks or a number of months before a significant reduction of the pandemic’s threat takes place (https://nnw.fm/ys2v9).
Autonomous security developer Knightscope has noted that one benefit of its robotic security teams patrolling select businesses and agencies across five time zones is that they are “immune and have been continuing to patrol across the country despite the pandemic” (https://nnw.fm/FsKGD).
Now, the robots are also helping to provide a sense of COVID confidence by enabling elevated body temperature detection from wherever the sentries are located.
“The Centers for Disease Control and Prevention indicates that a person with a temperature of 100.4 degrees or greater has a ‘fever,’ a symptom of COVID-19,” a recent Knightscope announcement states (https://nnw.fm/v7YAD). “In an effort to help combat the spread of COVID-19, Knightscope developed a way for its clients to measure body temperatures of employees and visitors entering a facility.”
The Pew Research Center reported in March that 24 percent of workers didn’t have access to any kind of paid sick leave prior to the pandemic, as noted in The Deseret News (https://nnw.fm/t4McS). Only 13 states currently require employers to offer paid sick leave. Fewer states passed temporary new measures in response to the coronavirus. But the need for sick workers to stay home if they’ve been infected means that businesses are not only under pressure as staffing levels become more critical, but also in dealing with the financial realities that their employees are wrestling with.
Knightscope’s new solution ultimately protects companies and their employees from the threat of virus transmission in the workplace as well as from the traditional external safety issues surrounding potential crime, fire and property damage matters.
“Our long-term ambition is to make the United States of America the safest country in the world,” the company’s website states.
For more information, visit the company’s website at www.Knightscope.com.
Visit www.Knightscope.com/invest for a summary of Knightscope as an investment, with a blue Instant Messaging button for direct contact with their CEO.
DISCLAIMER: You should read the Offering Circular and risks related to this offering before investing. This Reg A+ offering is made available through StartEngine Primary, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.
NOTE TO INVESTORS: The latest news and updates relating to Knightscope are available in the company’s newsroom at https://nnw.fm/Knight
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork.
Whether you’re looking for penny stocks to buy on Robinhood, ETrade, TD, Webull, Interactive Brokers, or other platforms, everyone has 1 goal. At least I would hope everyone has one goal, which is to make money. One of the interesting parts about that mix of brokers is some restrict access to certain stocks. Take penny stocks on Robinhood or Webull for instance. The vast majority are limited to just NASDAQ and NYSE stocks. When it comes to OTC penny stocks , these “mobile-first” platforms are very limited.
Keep in mind, however, that “listed” stocks (Nasdaq & NYSE) tend to get more attention from investment firms, in general. With that also comes interest from analysts. The Wall Street firms follow countless companies, weighing in on everything from earnings growth to pipeline products or treatments. What I will say is that analysts aren’t fail proof. But they do focus their energy on finding opportunities or risks that the investing community can use.
Penny Stocks To Buy According To Analysts
In my opinion, just because there’s a Buy or Sell rating doesn’t necessarily mean anyone should “definitely” buy or sell that stock. If anything it gives you a glimpse of sentiment. Can analyst actions impact stock prices? Yes and we’ve seen that in real-time over the last few weeks. But after the dust settles, it’s up to traders themselves to digest the information and fold it in with the rest of their analysis. Keeping this in mind, here are a few penny stocks with Buy ratings that also have hefty price targets. Will these find their way on your watch list before next year?
Penny Stocks To Buy [Lake Street Capital]: SeaChange International Inc.
SeaChange International Inc. has a Buy rating from Lake Street Capital. The firm also has placed a $2 price target on SeaChange shares. This puts their SEAC stock forecast 92% higher than Tuesday’s closing price.
It’s no secret by looking at the chart that SEAC has experienced a rough year. But it’s the last few months that I’m looking at right now. Since October 29th, shares have bounced from around $0.70 to highs this week of $1.10. Initially, the move was correlated with the general tech industry’s rebound following vaccine news. However, in December, things have become a bit more active both in the market and with the company.
The company reported strong earnings per share compared to estimates. SeaChange recorded a 10 cent loss per share in comparison to Wall Street’s 12 cent loss per share. Some things that helped with this had to do with strong demand from content owners for SeaChange’s new ‘Video Apps’ platform. This allows content owners to actually launch direct-to-consumer TV and video applications directly through Smart TVs and connected platforms.
What To Watch With SeaChange
Thanks to COVID, there are more people streaming entertainment. The company’s video apps platform allows independent content owners to distribute content while also leveraging a unique monetization strategy via advertising.
[Read More] Best Penny Stocks To Buy Right Now? 3 Under $3 For Your Watch List
Last week SeaChange discussed its SeaChange Framework. With the way people are accessing entertainment, digital platforms could be a focus in 2021.Scott Apgar, VP Advanced Advertising explained the idea further, “Many SeaChange Content Owner customers across the globe are using the Framework today to generate new advertising revenue streams through the automated sale of their ad inventory.”
Penny Stocks To Buy [Maxim Group]: VistaGen Therapeutics
VistaGen Therapeutics Inc. is another one of the trending penny stocks to watch this month. Right now Maxim Group has a Buy rating on the stock along with a $5 price target. This puts Maxim’s VTGN stock forecast roughly 233% higher than Tuesday’s closing price. Similar to SeaChange, a lot of the momentum has come in December. In fact, since the start of the month, VTGN stock has climbed over 90%. What’s more is that since March, shares have bounced as much as 416%. The overall trend on the chart is clearly bullish. But as I said, some of the most aggressive moves have come this month.
Specifically, the company announced that it would raise $100 million in a public offering at $0.92. Now many times companies announce financing deals, the stocks tend to crumble. However, in this case, VistaGen’s stock was trading right around the same levels as the money was raised at. In response to the new cash, VTGN stock popped big. That’s likely in light. of the use of proceeds as well. VistaGen intends to use the money for research, development, manufacturing, and regulatory expenses associated with continuing the development of its pipeline treatments. This includes its PH94B, PH10, AV-101, and potential drug candidates to expand its CNS pipeline and for other working capital and general corporate purposes.
What To Watch With VistaGen
Aside from these latest highlights and fresh capital, there are other things to keep in mind. One of which is actually who invested in the latest funding round. Lead investors that participated in the offering include Acuta Capital, New Enterprise Associates, OrbiMed, and Venrock Healthcare Capital Partners. These are notable firms focused on advancing early-stage public companies. A few are specific to the biotech industry itself. Keep in mind that an extra $100 million doesn’t hurt especially when it comes to biotech pipelines.
“We are making significant progress in preparing PH94B for launch of a pivotal Phase 3 study for acute treatment of anxiety in adults with social anxiety disorder in the second quarter of 2021. After reaching consensus with the FDA on the key components of the study design, it will be very similar to the statistically significant Phase 2 study of PH94B in social anxiety disorder. We are also working with the FDA to finalize details for our Phase 2A study of PH94B in adjustment disorder, which we are planning to initiate in early 2021,” said Shawn Singh, Chief Executive Officer of VistaGen in the company’s fiscal 2021 Q2 business update.
Penny Stocks To Buy [Roth Capital]: Hepion Pharmaceuticals Inc.
Hepion Pharmaceuticals Inc. has one of the highest price targets of the bunch. Roth Capital currently has a Buy rating on the stock as well as an $8 price target. That puts the firm’s HEPA stock forecast 284% higher than Tuesday’s closing price. The company has focused its efforts on developing treatments for non-alcoholic steatohepatitis or “NASH”.
Read More
The last few months have been volatile to say the least. Shares of HEPA stock were trading north of $4.70 during the summer. But several financing announcements did. the opposite of what VistaGen experienced. The penny stock eventually reached a low of $1.51 at the end of November.
December has been a much different month. Shares have actually recovered significantly by over 20% month-to-date. The excitement continued Tuesday morning as the company announced that an independent Data Safety Monitoring Board approved the continuation of the company’s Phase 2a ‘AMBITION’ clinical trial of its lead candidate, CRV431 in NASH. The final cohort is expected to be completed early next year.
What To Watch With Hepion
Heading into the end of the year, new information emerged late in the afternoon on Tuesday that should be noted. Hepion announced top-line data from the low dose cohort in its Phase 2a ‘AMBITION’ clinical trial of CRV431. The results of the low dose group showed that CRV431 was “generally safe and well-tolerated.” Furthermore, the pharmacokinetics “indicated that blood concentrations of CRV431 were similar to those observed in earlier Phase 1 studies in healthy volunteers, suggesting that the PK profile in moderate-to-severe NASH patients did not appear to be altered by disease.”
A second dosing cohort of 225 mg CRV431, which is the high dose is ongoing. Final results from both dosing cohorts are expected after the high dose group has completed active dosing, followed by a 14-day observation period.
In the last two years, the debate over the legalization of cannabis for adult use has dragged on in New York State. However, this may take a turn for the better next year as the state’s legislature goes back to Albany, despite the Democrats being divided on various aspects on the issue, which may make negotiations a tad bit difficult.
The main concern seems to be how the state will utilize the revenue generated from the recreational-use cannabis industry. According to forecasts from the state, the cannabis industry is expected to generate roughly $300 million each year once the industry stabilizes. The Marijuana Regulation and Taxation Act, which is supported by some Democrats in the legislature, would ensure that half of the revenue generated is set aside and invested in the communities that had drug laws by the state enforced at higher rates.
The bill is sponsored by the chair of the Finance Committee, state senator Liz Krueger, and Assembly Majority Leader Crystal Peoples-Stokes, D-Erie. Krueger stated that the individuals she has been working with are committed to this model and believe that revenue should be utilized for social justice purposes, because it would support communities of color that had been greatly affected by the drug wars.
Data from the state shows that, historically, in the city of New York, people of color are arrested more often for cannabis possession when compared to their white counterparts. According to the “Times Union,” this is also true for cities such as Albany. Clauses in the proposal stated that the state would develop a fund whose purpose would be to provide grants for local government entities and community-based NGOs that support those communities’ needs, including legal services and job placement.
While Democrats agree with the idea broadly, they disagree on a few minor details. Gov. Andrew Cuomo introduced a Cannabis Regulation and Taxation Act in 2019, which highlights similar issues such as the MRTA. However, it doesn’t set aside a specific amount of funds to be allocated to communities affected by the war on drugs. This has become a bone of contention for the legislature.
Apart from this, other issues include the different tax rates set for consumers in the marijuana market, with the legislature bill setting the rate at 18% and Cuomo’s legislation creating a 20% tax for consumers.
In addition to this, legislators can’t agree on whether to allow consumers to cultivate their own cannabis plants at home and, if so, how this would be regulated. Cuomo’s plan does not allow this option while Krueger’s does.
Road safety is also another issue, seeing as there’s no easy way to test whether an individual is driving under the influence of cannabis.
Away from the legalization debates in New York, Arizona-based The Alkaline Water Company Inc. (CSE: WTER) (NASDAQ: WTER) is carving out a name for itself as the maker of the best pH-balanced alkaline drinking water. In additions, its CBD-infused products are very popular.
NOTE TO INVESTORS: The latest news and updates relating to The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER) are available in the company’s newsroom at http://cnw.fm/WTER
About CNW420
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CNW420.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have questions or are you interested in working with CNW420? Ask our Editor
CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CNW420 is part of the InvestorBrandNetwork.
- One of recent history’s largest snowstorms struck United States’ Eastern seaboard in mid-December
- Over 60 million Americans were placed under winter storm advisories, with the Governors of New York and Pennsylvania declaring state of emergency
- 2020 has been characterized by its extraordinary storm season, which has already seen six major hurricanes and 30 tropical storms cause estimated $38 billion in overall damage
- Sustainable Green Team specializes in providing environmentally beneficial solutions for tree, storm waste disposal
- Company witnessing surge in demand for tree recovery and debris collection services as result of ongoing storm season
The week of December 14, 2020 brought with it the biggest winter storm to hit the United States’ mid-Atlantic seaboard in years. Heavy snows moved into New York City with the National Weather Service forecasting that some areas in northeastern United States would receive as much as 20 inches of snow as a result of the moisture-laden system, placing it amongst the heaviest December snowstorms on record (https://ibn.fm/fLAjw). However, the Sustainable Green Team (OTC: SGTM), a leading provider of environmentally beneficial solutions for tree and storm waste disposal, has been preparing for just such an eventuality in a year which has already been marked by a series of extraordinary weather events.
The Sustainable Green Team’s wholly owned subsidiary, National Storm Recovery LLC, is composed of a team boasting expertise in dangerous tree removal, debris hauling and debris management. The company’s management team assesses storms by deploying its mobile command center to designated sites and then strategizing with its national partners, which include government agencies, prime contractors and subcontractors.
While damage assessments from the snowstorm are yet to be disclosed, they are likely to be significant in nature. Over 60 million Americans have been placed under winter storm advisories, watches and warnings in a vast swathe of area ranging from northern Georgia to New England, with the governors of New York and Pennsylvania responding to the snowstorms by declaring a state of emergency – as a cold weather front, wind gusts topping 50 mph and high levels of snowfall ravage the eastern seaboard (https://ibn.fm/Psxa3). Meanwhile, state utilities have warned residents to be prepared for potential power outages, in the event of downed power lines or other related mishaps (https://ibn.fm/EUHqN).
“Confidence is high that this winter storm will result in significant impacts, including travel disruptions and power outages across much of the mid-Atlantic and southern New England,” the Weather Prediction Center noted (https://ibn.fm/ob3Or).
The 2020 Atlantic hurricane season was one that was destined for the record books before it even started. Meteorologists began calling for an above-average storm season as early as December 2019 (https://ibn.fm/OXmvY), with predictions of 15-20 named storms and four major hurricanes. However, in remarkable contrast to initial forecasts, the Atlantic hurricane season has thus far comprised of upwards 30 tropical storms, 13 hurricanes and six major hurricanes with initial assessments estimating the cumulative economic impact of the storms at over $38 billion (https://ibn.fm/3WIZb).
Nonetheless, the active storm season has led to a commensurate increase in the demand for tree recovery/collection services, which in turn has translated into greater sales for the Sustainable Green Team’s services.
“Storm recovery is a multibillion-dollar business, and we are prepared to help in any cleanup process,” stated SGTM CEO and Director Tony Raynor.
To learn more about Sustainable Green Team Ltd., view the investor presentation at https://ibn.fm/0TBkF.
NOTE TO INVESTORS: The latest news and updates relating to SGTM are available in the company’s newsroom at http://ibn.fm/SGTM
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.
Reincorporation Proposal Received Overwhelming Support Among Shares Voted
NEW YORK, Dec. 29, 2020 — Predictive Oncology (NASDAQ: POAI) (the “Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that its Board of Directors has decided to cancel its Special Meeting of Stockholders that was originally scheduled for December 1, 2020. On that date, the meeting was adjourned to December 30, 2020 because a quorum was not reached. As of December 30, 2020, approximately 47% of the outstanding shares as of the record date have been voted, and therefore a quorum has still not been reached. The Board of Directors has determined that it is not practical to incur the expense of adjourning the meeting further to continue to solicit proxies, because approval of the reincorporation proposal would require the affirmative vote of a majority of the Company’s outstanding shares (not simply a majority of the shares voted).
The Board notes that, of the shares that were voted at the Special Meeting, nearly 88% of the shares were voted FOR the reincorporation from Delaware to Nevada. In the future, the Board intends to continue to seek stockholder approval for reincorporation, due in part to the oppressive franchise taxes charged by Delaware.
About Predictive Oncology Inc.
Predictive Oncology (NASDAQ: POAI) operates through three segments (Skyline, Helomics and Soluble Biotech), which contain four subsidiaries: Helomics, TumorGenesis, Skyline Medical and Soluble Biotech.
Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. TumorGenesis Inc. specializes in media that help cancer cells grow and retain their DNA/RNA and proteomic signatures, providing researchers with a tool to expand and study cancer cell types found in tumors of the blood and organ systems of all mammals, including humans. Skyline Medical markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. Soluble Biotech is a provider of soluble and stable formulations for proteins including vaccines, antibodies, large and small proteins and protein complexes.
Forward-Looking Statements
Certain matters discussed in this release contain forward-looking statements. These forward-looking statements reflect our current expectations and projections about future events and are subject to substantial risks, uncertainties and assumptions about our operations and the investments we make. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future revenue and financial performance, projected costs, prospects, plans and objectives of management are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “would,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Our actual future performance may materially differ from that contemplated by the forward-looking statements as a result of a variety of factors including, among other things, factors discussed under the heading “Risk Factors” in our filings with the SEC. Except as expressly required by law, the Company disclaims any intent or obligation to update these forward-looking statements.
Investor Relations Contact:
Hayden IR
James Carbonara
(646)-755-7412
Cybin Inc. ( NEO:CYBN ) (“ Cybin ”), a life sciences company focused on psychedelic pharmaceutical therapies, announces the unaudited financial results of Clarmin Explorations Inc. (now Cybin Inc.) for the three month period ended October 31, 2020. A copy of the unaudited consolidated financial statements prepared in accordance with International Financial Reporting Standards and the corresponding management’s discussion and analysis for the three months ended October 31, 2020 can be found under Cybin’s profile at www.sedar.com .
About Cybin
Cybin is a life sciences company advancing psychedelic pharmaceutical treatments for various psychiatric and neurological conditions. Cybin is developing technologies and delivery systems, aiming to improve bioavailability, to potentially achieve the desired medicinal effects of psychedelics at low dosage levels. The new delivery systems are expected to be studied through clinical trials to confirm safety and efficacy.
Cautionary Notes and Forward-Looking Statements
Certain statements in this press release constitute forward-looking information. All statements other than statements of historical fact contained in this press release, including, without limitation, statements regarding Cybin’s future, strategy, plans, objectives, goals and targets, and any statements preceded by, followed by or that include the words “believe”, “expect”, “aim”, “intend”, “plan”, “continue”, “will”, “may”, “would”, “anticipate”, “estimate”, “forecast”, “predict”, “project”, “seek”, “should” or similar expressions or the negative thereof, are forward-looking statements. These statements are not historical facts but instead represent only Cybin’s expectations, estimates and projections regarding future events. These statements are not guaranteeing future performance and involve assumptions, risks and uncertainties that are difficult to predict. Therefore, actual results may differ materially from what is expressed, implied or forecasted in such forward-looking statements. The forward-looking information and forward-looking statements included in this press release are made as of the date of this press release. The Company does not undertake an obligation to update such forward-looking information or forward-looking information to reflect new information, subsequent events or otherwise unless required by applicable securities law. Readers should not place undue importance on forward-looking information and should not rely upon this information as of any other date.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201229005459/en/
Investors:
Tim Regan/Scott Eckstein
KCSA Strategic Communications
Cybin@kcsa.com
Lisa M. Wilson
In-Site Communications, Inc.
lwilson@insitecony.com
Media Liaisons :
Jackie Poriadjian
Chief Marketing Officer, CYBIN
Jackie@cybin.com
Annie Graf
KCSA Strategic Communications
agraf@kcsa.com
- A novel anthracycline believed to be effective in combatting deadly glioblastoma brain cancers by crossing the blood-brain barrier and zeroing in on the tumor will begin Phase 2 trials during Q1 of next year
- The drug, Berubicin, is being developed by CNS Pharmaceuticals after initial testing nearly 15 years ago resulted in improvements among some subjects, including one who has survived cancer-free since that time
- The company, in collaboration with Polish sub-licensee partner WPD Pharmaceuticals, plans a multinational staged series of trials that will attempt to keep time and costs to outcome at a minimum
- As part of the effort, CNS and WPD plan to conduct the first-ever pediatric Phase 1 trial of Berubicin in children with no other recourse
Brain cancers that are relentless and effectively incurable have caught the attention of drug maker CNS Pharmaceuticals (NASDAQ: CNSP), which is working to complete testing of its lead candidate in hopes of finding a cure against those central nervous system disorders.
The drug, Berubicin, is an anthracycline with the novel distinction of being able to cross the blood-brain barrier to combat tumors — something all other anthracyclines are unable to do. Nearly 15 years ago, Berubicin was the subject of a Phase 1 safety trial conducted by Reata Pharmaceuticals. The limited study resulted not only in a finding of safe usage, but in two patients reductions of greater than 25 percent in the size of their tumors (one achieved an 80% reduction in the tumor) while another patient became cancer-free (known as a durable complete response) and has remained cancer-free to the present, as noted in a recent company webinar (https://ibn.fm/WnXTx).
CNS obtained rights to Berubicin and its related clinical data. The company was awarded Orphan Drug Designation (“ODD“) for Berubicin in treating malignant glioma cancers (an indication much broader than the current investigational target of glioblastoma multiforme) and announced Nov. 17 that it had filed an Investigational New Drug (“IND”) application with the U.S. Food and Drug Administration (“FDA”), which had been accepted for review (https://ibn.fm/T6idd). Thirty days later the Company announced that its IND for Berubicin for the treatment of Glioblastoma Multiforme (“GBM”) was approved and in effect as filed with the US Food and Drug Administration (“FDA”).
CNS continues to methodically develop its plan of attack with Berubicin, planning to launch a Phase 2 trial during the first quarter of 2021, which will involve randomized and controlled comparative administration of Berubicin and the chemotherapy drug lomustine to 243 patients. Lomustine is widely considered to be the second-line standard-of-care therapy despite not being formally approved as such.
The trial will take place at about 60 study centers in North America, Europe and the Asia-Pacific region, searching for proof that Berubicin patients may benefit from reduced tumor size or even just from arrested development of the tumor’s growth. And, ultimately, the overall survival of the patients, of course.
Glioblastoma patients have been found to have a median survival rate of only 14.6 months from the date of the malignancy’s diagnosis. With surgical intervention, the cancer tends to recur and adapt to pharmaceutical interventions. The Phase 1 patient’s survival without cancer recurrence during the past 14 years is seen as significant cause for optimism.
Concurrent with the multinational Berubicin trial, CNS Pharmaceuticals is partnering with Europe’s WPD Pharmaceuticals to launch a first-ever Phase 1 Berubicin pediatric safety trial in Poland during Q1 of 2021 for children who have the GBM tumor and have run out of other medical options. WPD will also conduct a Phase 2 trial on the adult use of Berubicin. Under the licensing agreement, WPD will pay a minimum of $2 million on the development of Berubicin and pay CNS a royalty fee on sales.
WPD received a $6 million development grant in January from the European Union to complete the two trials, which significantly increases CNS’s ability to complete the Berubicin trials without the degree of spending and equity dilution that might have occurred otherwise. In an effort to further control those outlays of capital, CNS CEO John Climaco stated during the webinar that the company will complete the trials in stages over the next two to two-and-a-half years, funding each successive stage as results from achieved milestones show the efficacy of continuing to proceed forward.
The trials are expected to cost $30 million to $35 million by the time they are completed. In the meantime, the company also hopes positive results from the trials will convince the FDA to grant Berubicin an expedited pathway to approval, which would reduce the time and cost of the trials to an even greater degree. The company recently announced the sale of $10 million of stock in a public offering and has also secured up to $15 million in potential equity financing via an equity line facility with Lincoln Park Capital.
For more information, visit the company’s website at www.CNSPharma.com
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Loop Insights (TSX.V: MTRX) (OTCQB: RACMF) CEO Rob Anson has released a recent shareholder letter calling 2020 an extraordinary year and outlining the company’s significant accomplishments. A provider of contactless solutions and artificial intelligence (“AI”) to drive real-time insights, enhanced customer engagement, and automated venue tracing to the brick-and-mortar space, Loop Insights has seen a year full of firsts and noteworthy partnerships, products and financing. The letter provided a review of the highlights for the company, including its selection to join Amazon Web Services Partner Network and the interactive webinar RACMF hosted with Amazon Web Services to showcase Loop’s venue-tracing capabilities. Loop Insights also had two products accepted into the Telus IoT Marketplace: its proprietary contact-tracing product and its Insights service, which consists of RACMF’s IoT Fobi device, Loop Cloud API, and AI Insights Portal. In addition, Loop announced retail partnerships with both Vend and Shopify and played a key role in the first-ever venue bubbles in a live environment. Most recently, the company announced that it had joined KABN Systems NA Holdings Corp. (CSE: KABN), Liquid Avatar, Lumedic, the Campus Agency and TripXpertz to form a consortium to manage verifiable identity credentials for COVID-19 vaccinations; Loop also announced the January 2021 launch of its Digital Connect Health Platform, a fully integrated digital healthcare solution designed for both government and private sector. “As shareholders can see from this year in review, Loop had an incredible year in 2020, and more importantly, is positioned with the right partners, products, pipeline, and financial resources to make the same quantum leap in 2021,” Anson stated in the press release. “Our success is reflective of our hard work and the exceptional quality of our people. Our team has grown and we’ve welcomed many passionate members who continue to drive innovation here at Loop. Despite the challenges created by the COVID-19 pandemic, the Loop team has overcome all obstacles and continues to work to drive the growth of the company, whether working remotely or together in our Vancouver office. We can’t wait to get back to work and deliver more big wins for our shareholders.”
To view the full press release, visit http://ibn.fm/fQlT1
About Loop Insights Inc.
Loop Insights is a Vancouver-based Internet of Things (“IoT”) technology company that delivers transformative artificial intelligence (“AI”) automated marketing, contact tracing and contactless solutions to the brick-and-mortar space. Its unique IoT device, Fobi, enables data connectivity across online and on-premise platforms to provide real-time, detailed insights and automated, personalized engagement. RACMF’s ability to integrate seamlessly into existing infrastructure and customize campaigns according to each vertical creates a highly scalable solution for its prospective global clients that span industries. Loop Insights operates in the telecom, casino gaming, sports and entertainment, hospitality and retail industries in Canada, the United States, the UK, Latin America, Australia, Japan and Indonesia. Loop’s products and services are backed by Amazon’s Partner Network and sold through the TELUS IoT Marketplace. For more information about the company, please visit www.LoopInsights.ai.
NOTE TO INVESTORS: The latest news and updates relating to RACMF are available in the company’s newsroom at http://ibn.fm/RACMF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, was featured in an equity research report by Maxim Group LLC. The piece discusses VistaGen’s strongest positioning yet, based on its pharmaceutical pipeline coupled with financing and a rising mental health pace. The report reads, “On 12/18, VistaGen announced pricing of an equity financing, raising gross proceeds of $100M (~$93M net) and bringing the company’s cash balance to ~$103M. Importantly, the financing included participation of some leading institutional health care investors, which in our view is further validation of VistaGen’s mental health-focused pipeline (NMDA modulation, nasal-active pherines (PH94B, PH10)) and management’s ability to execute. We are also now factoring in PH10 into our model and the increased cash balance, which raises our PT to $5, from $3.”
To view the full report, visit http://ibn.fm/zbWAX
About VistaGen Therapeutics Inc.
VistaGen is a biopharmaceutical company committed to developing and commercializing innovative medicines with potential to go beyond the current standard of care for anxiety, depression and other CNS disorders. Each of VistaGen’s three drug candidates has a differentiated potential mechanism of action, has been well-tolerated in all clinical studies to date and has therapeutic potential in multiple CNS markets. For more information, please visit www.VistaGen.com and connect with VistaGen on Twitter, LinkedIn and Facebook.
NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at http://ibn.fm/VTGN
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
- Analysts recommending small cap stocks for both growth and value amid large cap overvaluations, decreased momentum
- SRAX subsidiary LD Micro hosted 13th Annual Main Event featuring nearly 250 prominent and emerging micro-cap companies
- Two-day virtual conference was hosted on SRAX’s Sequire platform from December 14-15, 2020
- 2 million+ active small cap investors invited from LD Micro’s loyal investor base
Large cap technology growth stocks like Amazon and Tesla have seen a massive wave of investor momentum as a result of COVID-19. The resulting overvaluations and decreased momentum in recent weeks, however, are prompting some analysts to recommend a shift back to small cap value investments (https://ibn.fm/FSEQm). LD Micro, a prominent resource to the microcap world, recently covered nearly 250 established and emerging micro-cap companies at its 13th Annual Main Event on December 14-15, 2020. The event was hosted by SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies, on Sequire – its virtual events and investor analytics SaaS platform.
Despite the impressive gains seen on the Nasdaq this year, the index has returned 10.5% so far in December while the Russell 2000 and Russell Micro-Cap indices have returned 25.8% and 27.6%, respectively. This wide difference in returns and valuations is prompting investors to focus their attention on small cap value stocks – a trend that is expected to continue well into 2021 (https://ibn.fm/JN2F6).
LD Micro, now a wholly owned SRAX subsidiary, has been a respected source of quality investor information to the small cap investment community for nearly 15 years. Almost 2 million active small cap investors from its loyal base have been invited to the two-day virtual conference that will feature an all-new format that promises to deliver a unique experience for all participants. Along with nearly 250 companies across the micro-cap world, the special event also featured special keynotes by guests such as Shaquille O’Neal & Brock Pierce.
The conference marks the debut of Sequire’s virtual events platform, a new addition to SRAX’s current suite of solutions for public companies that help them attract and engage new investors and existing shareholders in a single place.
“We are excited to bring together one of the largest communities of micro-cap investors to hear from amazing companies,” said SRAX Founder and CEO Christopher Miglino. “The LD Micro conference has a long history of driving awareness for companies and is just one of the many benefits that the Sequire platform brings to the table when helping public companies.”
The advent of new technology, coupled with increasing market complexity, has created a novel demand for sophisticated investor relations applications. SRAX provides those solutions through Sequire, its data-based SaaS software that addresses this demand through a suite of tools that helps public companies unlock the power of data to reveal investor behaviors and trends.
For more information, visit the company’s website at www.SRAX.com.
NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.
As part of a global push to reduce carbon emissions and improve air quality, several governments, cities and states have issued bans against the sale of internal combustion engine vehicles in favor of electric vehicles (“EVs”). Europe undoubtedly leads the race towards electrifying its roads thanks to its ambitious ICE vehicle bans, with at least seven European countries pledging to ban the sale of new ICE vehicles over the next 30 years.
But as EV adoption increases over time, will power grids in cities be able to handle the increased demand for electricity? The European Union saw a 122% increase in the electric and PHEV sales over the first three quarters of 2020, representing about 8% of total new vehicle sales. In Sweden, electric automobiles took up a 28% share of auto sales for the first nine months of this year translating to 56,559 PHEVs or fully electric vehicles bought.
Despite the uptick in EV adoption, Stockholm has less than 4,000 charging stations publicly accessible and will require 25,000 stations by 2030 to keep up with the demand for power, says Kristofer Fröjd, the head of business development at Stockholm’s power distributor Ellevio. Even if the city is able to install the required chargers in time, the country’s power grid is often stretched to capacity, especially during winter when demand peaks. In the future, EV drivers may have to deal with slower charging speeds as power providers balance the demand for domestic heat with transport needs.
According to Per Eckemark, Svenska Kraftnät’s grid executive manager, electric vehicles will consume almost 10% of Sweden’s electric output by 2045, up from 0.4%. Svenska Kraftnät, which is the country’s national transmission grid operator, plans to rebuild one-third or roughly 3,107 miles of the country’s grid at a cost of $17.9 billion by 2030. However, officials assert that the additional power output will not be enough to forestall the country’s grid from being severely strained come 2022.
The situation is almost identical in most territories that are phasing ICE vehicles out in favor of EVs. Britain will need 2.8 million chargers at a cost of $22.07 billion by 2035 to meet power demands. In Canada, the province of British Columbia is projected to be home to approximately 350,000 EVs by 2030, requiring an additional 1,050 gigawatts hours of electricity per year.
Meanwhile, the EV industry is surging forward as it attempts to address the rapidly changing needs of car buyers. Nowhere else is this revolution evident than in the recent announcement by Net Element (NASDAQ: NETE), a global payments solutions provider, revealing that it was in the process of merging with a EV manufacturer based in Southern California.
NOTE TO INVESTORS: The latest news and updates relating to Net Element (NASDAQ: NETE) are available in the company’s newsroom at http://ibn.fm/NETE
About Green Car Stocks
Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.
To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)
For more information, please visit https://www.GreenCarStocks.com
Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer
Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com
Green Car Stocks is part of the InvestorBrandNetwork.
Net Element (NASDAQ: NETE), a financial technology company in the process of transforming its business model to become a pure-play electric vehicle (“EV”) manufacturer through a pending merger with privately-held Mullen Technologies Inc., is poised as the EV sector has seen a sharp uptick in consumer demand and investor interest. Rising demand is driven by a combination of improved sector fundamentals coupled with positive industry news. A recent article discussing the company reads, “A potential combined Net Element-Mullen Technologies entity plans to leverage upon the surge in consumer demand within the electric vehicle space through the launch of its initial vehicle model – the Dragonfly K50—in the second quarter of 2021. The car model, developed in conjunction with China’s Qiantu Motors, will mark the company’s initial foray into the North American electric vehicle market, a venture which the company will further look to reinforce through the launch of its self-manufactured EV SUV, the Mullen MX-5, by the second quarter of 2022.”
To view the full article, visit https://ibn.fm/93wvE
About Net Element Inc.
Net Element operates a payments-as-a-service transactional and value-added services platform for small to medium enterprise (“SME”) in the U.S. and selected emerging markets. On Aug. 5, 2020, Net Element announced the execution of a definitive agreement to merge with privately-held Mullen Technologies Inc., a Southern California-based electric vehicle company in a stock-for-stock reverse merger in which Mullen’s stockholders will receive a majority of the outstanding stock in the post-merger company (the “contemplated merger”). The contemplated merger is subject to customary closing conditions, regulatory approvals and shareholder approval for both companies. For additional information, visitwww.NetElement.com.
NOTE TO INVESTORS: The latest news and updates relating to NETE are available in the company’s newsroom at http://ibn.fm/NETE
About Green Car Stocks
Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.
To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)
For more information, please visit https://www.GreenCarStocks.com
Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer
Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com
Green Car Stocks is part of the InvestorBrandNetwork.
Genprex (NASDAQ: GNPX), focused on developing life-changing therapies for patients with cancer and diabetes, has announced the closing of its registered direct offering of 3,116,884 shares of its common stock with a single health care-dedicated institutional investor. Genprex secured gross proceeds of $12 million, before deducting commissions and estimated expenses, with the offering priced at-the-market under Nasdaq rules at a price of $3.85 per share. “We believe that the closing of this transaction with a single, health care-dedicated institutional investor is further evidence that the potential of our gene therapies for cancer and diabetes is gaining recognition within the community of sophisticated health care investors,” said Rodney Varner, president and CEO of Genprex. “The proceeds will provide additional resources to conduct our Acclaim-1 and Acclaim-2 clinical trials, combining our gene therapy, REQORSA, with Tagrisso (by Astra Zeneca) and Keytruda (by Merck & Co.), respectively, for the treatment of non-small cell lung cancer, as well as continue the pursuit of our pre-clinical programs in cancer and diabetes, and to potentially acquire additional technologies for our pipeline.”
To view the full press release, visit http://ibn.fm/1gQH0
About Genprex Inc.
Genprex is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The company’s lead product candidate, “REQORSA(TM)” (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (“NSCLC”). REQORSA has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. REQORSA has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for REQORSA for NSCLC in combination therapy with osimertinib (AstraZeneca’s Tagrisso(R)) for patients with EFGR mutations whose tumors progressed after treatment with osimertinib alone. For more information, visit the company’s web site atwww.Genprex.com.
NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Cybin (NEO: CYBN), a mushroom life science company, is set to leverage opportunity amid growing research that demonstrates the significant role psilocybin could play in alleviating symptoms of major depression. According to a recent study conducted by Johns Hopkins Medicine and published in “JAMA Psychiatry,” only two doses of psilocybin accompanied with psychotherapy may lead to significant reductions in symptoms in adults with major depression (https://ibn.fm/ZpmzM). “The magnitude of the effect we saw was about four times larger than what clinical trials have shown for traditional antidepressants on the market,” stated Alan Davis, PhD., adjunct assistant professor of psychiatry and behavioral sciences at the Johns Hopkins University School of Medicine. A recent article discussing this reads, “These results confirm that Cybin, committed to becoming one of the first life science companies to develop a fully approved psilocybin product targeting depression, is on the right track. CYBN is intent on providing solutions to the more than 17 million people in the United States and 300 million people worldwide who suffer from depression. The company has been focusing its efforts on psychedelic drug development and unique delivery mechanisms and protocols that target psychiatric and neurological conditions.”
To view the full article, visit https://ibn.fm/QU6P6
About Cybin Inc.
Cybin is a life sciences company advancing psychedelic pharmaceutical treatments for various psychiatric and neurological conditions. Cybin is developing technologies and delivery systems, aiming to improve bioavailability, to potentially achieve the desired medicinal effects of psychedelics at low dosage levels. The new delivery systems are expected to be studied through clinical trials to confirm safety and efficacy. For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at http://ibn.fm/CYBN
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that it was featured in a broadcast via NetworkNewsAudio (“NNA”), a solution that delivers additional visibility, recognition and brand awareness in the investment community via distribution to thousands of syndication points. The audio press release covers CNS Pharmaceuticals’ Investigational New Drug (“IND”) application for its lead product candidate, Berubicin, for the treatment of Glioblastoma Multiforme (“GBM”). The IND is now approved and in effect as filed with the U.S. Food and Drug Administration (“FDA”). “Since becoming a public company, our clear focus has been on advancing the clinical development of Berubicin. We will now rapidly move to initiate our Phase 2 trial of Berubicin for adults with GBM and expect to begin enrolling patients in the first quarter of next year,” said John Climaco, CEO of CNS Pharmaceuticals. “The company will transform within the next several months as Berubicin becomes the subject of up to three active clinical trials, which include our randomized, controlled Phase 2 trial in the U.S., and 2 trials planned by our sublicensee WPD in Poland. We are entering an area with significant unmet medical need since the current treatment paradigm for GBM remains bleak, as this aggressive and currently incurable form of brain cancer continues to claim high mortality rates. We have a tremendous opportunity ahead of us as we continue our mission to improve patient outcomes for GBM and build on the promising results demonstrated by Berubicin in its Phase 1 clinical trial.”
To view the full press release, visit http://ibn.fm/kSVfH
About CNS Pharmaceuticals Inc.
CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. For more information, visit the company’s website at www.CNSPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at http://ibn.fm/CNSP
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced the pricing of an underwritten public offering of 5,000,000 shares of common stock and warrants to purchase up to 2,500,000 shares of common stock. According to the update, the shares of common stock and warrants are being sold together at a combined public offering price of $2.00 per share and warrant. The warrants will have an exercise price of $2.20 per share and will be immediately exercisable and expire five years from the issuance date. CNS Pharmaceuticals has granted a 45-day underwriter option for the purchase of up to an additional 750,000 shares of common stock and/or 375,000 warrants to cover over-allotments, if any. The company intends to use the net proceeds for its Phase 2 trial for Berubicin, other research and development, as well as for working capital. Subject to customary conditions, the offering is expected to close on or about Dec. 28, 2020. A.G.P./Alliance Global Partners is acting as the sole book-running manager for the offering.
To view the full press release, visit http://ibn.fm/Jo8Cf
About CNS Pharmaceuticals Inc.
CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. For more information, visit the company’s website at www.CNSPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at http://ibn.fm/CNSP
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Cardiff University researchers have been conducting tests to see whether it is feasible to sterilize personal protective equipment (PPE) used by health practitioners to combat the COVID-19 pandemic using dry heat and microwave ovens. The researchers’ findings were published in the “Journal of Hospital Infection.”
The group of researchers demonstrated that some respirators could be sterilized successfully in one and a half minutes using a baby bottle sterilizer that had water and an industrial-grade microwave oven.
Jean-Yves Maillard, a professor from Cardiff’s School of Pharmacy and Pharmaceutical Sciences who is also the study’s co-author, explained that the inability of frontline workers to access enough PPE puts both them and the patients they take care of at risk of getting the coronavirus. The researchers’ aim was to find out whether single-use masks could be used again after being safely decontaminated.
The scientists believe that decontaminating masks using a microwave could be used in emergency situations to increase the respirators available to frontline workers while also addressing any issues encountered with regard to supply.
During the study, the team introduced respirators and ran them through three microwave decontamination cycles. They discovered that the respirators reserved their capacitiea to filter viral-sized aerosols and other bacteria. However, the researchers also discovered that when surgical masks were microwaved, they lost their ability to filter aerosols.
Another co-author of the study, Michael Pascoe, also from the School of Pharmacy and Pharmaceutical Sciences, explained that surgical masks usually lose their efficacy when they get moist. The researchers supposed that disinfecting the masks using a microwave would cause a loss in their filtration capacity, which was established by the observations made in the lab.
The group of researchers, which also comprised School of Engineering academics, looked into the use of dry heat ovens as another sterilization method. Sterilization using dry heat does not require water, which makes it compatible with articles that can be damaged by moisture.
The researchers discovered that exposing respirators and surgical masks to dry heat at 70 degrees Celsius for one and a half hours effectively disinfected both PPEs. Additionally, both surgical masks and respirators maintained their ability to filter aerosols after three cycles of dry heat.
It should be noted that the researchers would not recommend using this method at home. School of Engineering’s Professor Adrian Porch explained that this is because domestic microwave ovens use rotating turntables and have a significantly lower power. So in order to achieve similar results, one would need to expose the protective equipment for a much longer period. Masks also have thin wires, which can catch fire when put in microwaves. In addition, researchers are not certain how this method of sterilization would impact the masks’ efficacy and functioning.
Aside from the coronavirus and face masks, many firms are hard at work seeking remedies to various health conditions. For instance, DarioHealth Corp. (NASDAQ: DRIO) shines as a provider of smartphone-based technologies which help those with chronic diseases to make durable lifestyle changes.
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Ibogaine is a psychoactive substance that triggers hallucinations; the substance is found in the Apocynaceae family of plants. Ibogaine has been used in spiritual ceremonies by the Bwiti tribe of Gabon for centuries. However, it wasn’t until the ’50s that ibogaine became popular in the West as a treatment for depression and addiction.
Despite this rising popularity, however, ibogaine isn’t a medicine per se as it may lead to heart attacks and it’s illegal in most countries. Still, it was used by researchers recently to develop a non-hallucinogenic, non-toxic chemical cousin that helps tackle addictive and depressive behaviors in rodents. This innovative treatment provides hope that in the future chemists may develop medicines for individuals that offer the therapeutic benefits of other psychoactive compounds including ibogaine, tailored to exclude potential side effects.
Many psychedelics, including psilocybin, ibogaine and LSD, have long been perceived as potentially effective treatments of depression and addiction. Apart from possessing a mechanism of action different from the psychiatric medicines currently in use, psychoactives also give rise to long-lasting effects after a few doses have been administered, which suggests that they may not only be efficacious but they may also treat more people.
Individuals who suffer from addiction and depression usually lose some of their prefrontal cortex’s synaptic connections. The prefrontal cortex in the brain is connected to social behavior, personality and decision-making. Ketamine and LSD are psychoactive compounds that have been shown to help with addiction and depression in some individuals. The two psychedelic compounds appear to help the neurons in the prefrontal cortex communicate better through encouraging dendritic spine growth.
David Olson, a chemical neuroscientist from the University of California, led researchers in a study that discovered tabernanthalog, a non-hallucinogen derived from ibogaine. The group of researchers synthesized 20 chemical analogs of ibogaine and discovered TBG, or tabernanthalog, to be the most promising compound that was free from hallucinogens and toxic substances. They tested the compound on rodents and noticed that it supported dendritic spine growth in both the rodents and in cells. One injection of TBG was found to protect an individual against a heroin use relapse for two weeks. The team published its research in the “Nature” journal, explaining that the compound did not lead to dependency because it did not stimulate the reward centers of the brain.
Additionally, the researchers noted that TBG binds to serotonin receptors, which are also targeted by psilocybin and LSD, suggesting that the compound provides its beneficial effects without causing hallucinations.
A number of companies have shown interest in the psychedelic space. A clear example is Canadian-based Cybin Inc. (NEO: CYBN), which is engaged in developing psychedelic medicines as well as functional mushroom products.
NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) are available in the company’s newsroom at https://ibn.fm/CYBN
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.
Creatd (NASDAQ: CRTD), the parent company of Vocal, has released a year-in-review overview for the proprietary technology platform. The update spotlights the creators, stories and milestones that distinguished the platform throughout 2020. In addition, the update notes how Vocal supported the creative community, helping it survive during a year that faced major challenges presented by the global pandemic. The update reported that Vocal creators submitted more than 120,000 stories while users spent an average of more than four minutes consuming those stories. In addition, Vocal creators received more than $400,000 in revenue throughout the year; $195,000 of that was earned through exclusive Vocal challenges. “It is important in today’s business environment for investors to acknowledge and understand that in order to build a valuable company, our management team and, more importantly, the platform must be contributing to more than just the bottom line,” said Creatd CEO and founder Jeremy Frommer. “As I have always said, and as our Year in Review confirms, when our creators succeed, the company succeeds.”
To view the full press release, visit http://ibn.fm/KzN0G
About Creatd Inc.
Creatd empowers creators, brands, and entrepreneurs through technology and partnership. Its flagship technology, Vocal, is a best-in-class creator platform. For more information about the company, please visit www.Creatd.com.
NOTE TO INVESTORS: The latest news and updates relating to CRTD are available in the company’s newsroom at http://ibn.fm/CRTD
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
- Loop Insights is an innovative data technology solutions provider developing contactless, digital wallet-based marketing, tracing and notification services
- During the COVID era, Loop’s venue management solution serves as a companion to contactless ticketing, and testing allowing attendees to receive alerts and notifications as well as proof of testing or vaccination and event / venue managers to monitor the same risk and deliver venue tracing alerts directly integrated with rapid testing.
- Following on the heels of the NBA’s massive COVID-free protective “bubble” experiment for the pro basketball season and playoffs, Loop served as the tech resource for two NCAA bubble events and successfully provided organizers the data they needed
- Loop is now partnering with rapid COVID test supplier Empower Clinics and aviation marketing consulting firm SimpliFlying to provide an international travel virus-protection bubble program, as well as a film industry bubble
- Loop intends to uplist from its TSX.V position to the broader TSX exchange, and then if successful to file with the Securities and Exchange Commission (“SEC”) in the United States to list on the NASDAQ
During the final weeks of 2020, the medical community has begun to experience real optimism in pushing back against the novel coronavirus pandemic that has sickened nearly 75 million people worldwide as of a week before Christmas, taking the lives of more than 1.6 million, and leaving some 20.5 million still in the throes of the illness with the Christmas holiday rapidly approaching (https://ibn.fm/MDktc).
With the rollout of one vaccine believed to be safe and effective in combating COVID-19 happening now, and additional vaccine approvals expected in the near future (https://ibn.fm/1Ivo8), business industry leaders are also tentatively beginning to adopt event and venue “bubble” practices that allow them to resume in-person, revenue-building activities while attempting to prevent infected people from attending. Bubble planning includes efficiently identifying any potential breach of the event / venue infection security net so that organizers can effectively provide contact-tracing warnings to participants who may have been exposed, as addressed in a report by event news outlet EventMB (https://ibn.fm/xRyvx).
Vancouver-headquartered Loop Insights (TSX.V: MTRX) (OTCQB: RACMF) is dedicating much of its focus on Internet of Things (“IoT”)-based contactless solutions to enabling renewed event / venue activity. The company has already successfully provided end-to-end venue tracing and alert notifications for two NCAA Division 1 basketball events and is expanding on its successes with bubble planning in non-sports markets such as the film and travel industries, as well as new sports events in 2021.
“There is simply no way to overstate the implications of our live environment Venue Bubble successes in Florida and Las Vegas over the past 10 days,” Loop Insights CEO Rob Anson stated about the NCAA events (https://ibn.fm/aLSVV). “With the whole world watching, including professional sports leagues and teams, college sports leagues and teams, world-renown venues and hospitality companies, Loop hit it out of the park and provided the world with the empirical data necessary to demonstrate our bubble solution is nothing short of world-class.”
The professional NBA basketball league set the initial standard for sports-related virus bubbles, creating a $190 million isolation zone at Florida’s Walt Disney World during the final eight games of the 2019–20 regular season and throughout the playoffs. The bubble was enacted in six phases between June and October, and no cases of COVID-19 were recorded by the teams participating in the bubble (https://ibn.fm/AUrR6).
Loop Insights’ IoT contactless venue management solution deployed in the NCAA events includes using smart wallet pass technology to manage tracing, testing, notifications and marketing. Attendees enter their personal information upon arrival, including their name and how to contact them, without having to rely on the exchange of hand written forms. The mobile wallets are used to authenticate the attendees’ information and to allow the exchange of information between the event / venue managers and the attendees regarding the data the venue requires, as explained in an October Loop webcast demonstrating the platform’s performance (https://ibn.fm/Q0feV).
The company’s recently announced expansion into virus-free bubble projects for the film industry (https://ibn.fm/dNvjQ) and the travel industry include a standout partnership with medical testing innovator Empower Clinics (CSE: CBDT) (OTC: EPWCF) (FRA: 8EC) and an MOU with aviation marketing consulting firm SimpliFlying to create an international airline travel bubble solution (https://ibn.fm/dFXHB).
Empower’s rapid antigen and antibody tests produce results in 15 minutes, providing the potential for a sense of security during the pandemic to airlines, cruise ships and the 182 countries currently in full or partial shutdown (https://ibn.fm/zpE9Q). The partners’ travel bubble product is now advancing talks for an agreement with the national tourism boards of the Dominican Republic, the Cayman Islands, the Bahamas, Jamaica and the Turks & Caicos islands, as well as the Iberostar, Bahia Principe and Hyatt Resorts, according to the company’s announcement.
Loop also recently announced its digital wallet and venue platform will support English, French and Spanish initially — a capability considered necessary as part of the partnership’s pursuit of nationwide agreements, particularly as Canada considers a unified solution with tracing, testing, and vaccination certification (https://ibn.fm/vAIfc).
The announcement includes notice that the company received $4.6 million from the exercise of warrants up to Dec. 10, which eliminates the need for any financing with the exception of strategic client partners that may want to invest in Loop in order to participate in its growth. Loop currently lists on the TSX.V and intends to uplist to the broader TSX exchange to increase its investment potential. If the TSX uplisting is successful, the company will eventually pursue filings with the Securities and Exchange Commission (“SEC”) in the United States to potentially list on the NASDAQ (https://ibn.fm/EZcxq).
For more information, visit the company’s website at www.LoopInsights.ai
NOTE TO INVESTORS: The latest news and updates relating to RACMF are available in the company’s newsroom at https://ibn.fm/RACMF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.
VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, has announced the closing of its $100 million underwritten public offering. The offering consisted of 63,000,000 shares of its common stock at an offering price of $0.92 per share, par value $0.001 per share, and 2,000,000 shares of its Series D convertible preferred stock at a public offering price of $21.16 per share. All of the securities in the offering were sold by VistaGen. Acuta Capital, New Enterprise Associates (“NEA”), OrbiMed and Venrock Healthcare Capital Partners, among others, participated in the offering as lead investors. VistaGen intends to use the net proceeds for research, development and manufacturing and regulatory expenses associated with continuing development of PH94B, PH10, AV-101, and potential drug candidates to expand its CNS pipeline and for other working capital and general corporate purposes. Jefferies LLC and William Blair & Company, L.L.C. acted as joint book-running managers for the offering and Maxim Group LLC acted as a financial advisor.
To view the full press release, visit: https://ibn.fm/3ORhO
About VistaGen Therapeutics Inc.
VistaGen is a biopharmaceutical company committed to developing and commercializing innovative medicines with potential to go beyond the current standard of care for anxiety, depression and other CNS disorders. Each of VistaGen’s three drug candidates has a differentiated potential mechanism of action, has been well-tolerated in all clinical studies to date and has therapeutic potential in multiple CNS markets. For more information, please visit www.VistaGen.com and connect with VistaGen on Twitter, LinkedIn and Facebook.
NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at http://ibn.fm/VTGN
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
If you have plans to start a business that deals with hemp products or cannabis, you should first look into the limitations, processes and rules involved. The business may have a promising future as various states in the United States have legalized the use of marijuana, with many hoping that others follow suit.
In addition to ensuring that you have obtained the permits and licenses required, there are a few more factors that you should consider before beginning a marijuana dispensary.
Regulations and rules
If you are planning to start your business in the United States, you should note that some states have strict restrictions on the use of cannabis. If you’re operating outside the U.S., you’ll find that many nations have legalized the consumption of cannabis, but many have specific regulations in place as well. Therefore, when it comes to the quantities and constituents of your products, ensure that no limits are crossed. This also means that you should acquire the required permits and licenses necessary to operate a dispensary in your area. This will help prevent your business or you from any legal dangers. Ensure that you do your research based on your area of operation.
Select your products carefully
It is important to be knowledgeable on the specific variations and types of products that you plan to sell before opening a dispensary. Various varieties of hemp and marijuana strains are available on the market. Each hemp and marijuana strain may produce different effects in consumers after consumption. To give provide the intended effects, you should select the right strains. Additionally, highg-quality products go a long way, so never compromise on quality.
Your business type
Different types of businesses exist in the marijuana industry. Some may have you play the role of a retail provider of marijuana products and strains while others may have you growing new marijuana strains and selling them. Make sure that you file your business as the proper entity as described by the state. How you register your business may affect the taxation and operation policies, so take note.
In addition to the factors mentioned above, how you market your business and the reputation of your business are both important. Make certain that you promote your services, especially on social media to help increase foot traffic in your store.
Maintaining and cultivating trust among your consumers is important for the reputation of your business. This can be done by selling high-quality cannabis or hemp products that produce the expected results. Being available to answer any questions your consumers may have concerning various products will be good for the business as well.
Many companies that have found their niche are performing well in the cannabis market. For example, The Alkaline Water Company Inc. (CSE: WTER) (NASDAQ: WTER) added a line of CBD-infused topical products and edibles to its premium bottled alkaline water.
About CNW420
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CNW420.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have questions or are you interested in working with CNW420? Ask our Editor
CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CNW420 is part of the InvestorBrandNetwork.
- Recent interview on CNBC featured prominent analyst advising investors against “egregiously expensive” tech stocks
- SGTM is profitable company that transforms natural waste into organic gardening products, playground surface material
- Recent financial results include Q3 revenue of $5.9 million, 4,817% increase in gross profit during first half of 2020 when compared to all of 2019
- Clients include The Kroger Co., Circle K, 7-Eleven, Menards Inc. and Old Castle Lawn & Garden
COVID-19 has sent the global economy into a tailspin, forcing the closure of hundreds of thousands of businesses along with the loss of millions of jobs. The stock market, however, appears to have decoupled from reality as it sets record highs amid this global economic catastrophe (https://ibn.fm/JcHkb). Sustainable Green Team (OTC: SGTM), a leading provider of environmentally beneficial solutions for tree and storm waste disposal, is a small but bright light among thousands of overvalued stocks, offering investors an opportunity to invest in an ethical, sustainable and profitable company.
MBMG Group Managing Director Paul Gambles recently gave an interview on CNBC advising investors to avoid “scarily priced” IT and consumer discretionary stocks, claiming that such investments were “egregiously expensive” (https://ibn.fm/t7WmY). Citing recent statistics from the MSCI World Consumer Discretionary Price Index and the MS World Information Technology Price Index – both of which have shot up by 85% and 75% respectively since last March – Gambles suggested that these types of stocks had benefited from shifts into digital and e-commerce amid COVID-19, but noted that the trend would not last much longer.
While momentum stocks in the S&P 500 have risen 28% so far this year, high-quality investments in discretionary stocks characterized by high dividends and low volatility have actually fallen. Adding to the confusion is the fact that most well-known tech “giants” such as Uber, Spotify and Airbnb have never actually turned a profit (https://ibn.fm/zrIAs). The resulting situation is creating confusion among investors and analysts struggling to make sense of a market that appears to be largely driven by investor speculation.
While SGTM does not have a digital platform, app, or plans to launch satellites into space, it does offer an opportunity to invest in a profitable company that takes sustainability seriously. Through its subsidiaries and partners, SGTM collects tree debris caused by storms and hurricanes and transforms it into environmentally friendly gardening mulch products and certified organic playground surfacing material.
Mulch is a multi-million dollar business that provides benefits to the earth, including natural weed control, temperature regulation, moisture retention and soil erosion prevention. Rather than allow tree debris to burden landfills, SGTM transforms it into a valuable product that is sold nationwide through contracts with corporate giants like The Kroger Co., Circle K, 7-Eleven, Menards Inc. and Old Castle Lawn & Garden.
Unlike many tech stocks making headlines in the financial markets, SGTM actually turns a profit. Besides growing significantly in 2020, the company recently reported $5.9 million in Q3 revenue (https://ibn.fm/H1s7t) along with an impressive 4,817% increase in gross profit during the first half of 2020 when compared to all of 2019 (https://ibn.fm/s6O8t). With plans to uplist to NASDAQ in the near future, the company has completed a 2-year audit and commenced its FORM-10 process to become fully reporting.
In an investment environment rife with volatility and speculation, SGTM offers synergistic solutions that benefit the environment while offering investors an excellent opportunity to purchase shares in a sustainable business. The company is committed to continue driving forward its mission while meeting the increasing demand for sustainable solutions to serious environmental issues.
To learn more about Sustainable Green Team Ltd., view the investor presentation at https://ibn.fm/EBY3V.
NOTE TO INVESTORS: The latest news and updates relating to SGTM are available in the company’s newsroom at http://ibn.fm/SGTM
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.
Predictive Oncology (NASDAQ: POAI), a knowledge-driven precision medicine company focused on applying data and artificial intelligence (“AI”) to personalized medicine and drug discovery, is positioned to play a critical role in the precision oncology industry. The company integrates AI technology with oncologists’ clinical decision-making processes, paving the way for improved health outcomes. A recent article discussing this reads, “POAI is focused on the use of data and artificial intelligence to develop personalized cancer therapies through its trove of valuable assets, including a database of clinically validated historical and outcome data from patient tumors, an in-house Clinical Laboratory Improvement Amendments (‘CLIA’)-certified lab, a ‘smart’ patient-derived tumor profiling platform, an in-house bioinformatics artificial intelligence platform, and a proprietary approach to growing tumors in the lab to rapidly develop patient-specific treatment options.”
To view the full article, visit: https://ibn.fm/GyjPp
About Predictive Oncology Inc.
Predictive Oncology operates through three segments (Skyline, Helomics and Soluble Biotech), which contain four subsidiaries: Helomics, TumorGenesis, Skyline Medical and Soluble Biotech. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. TumorGenesis Inc. specializes in media that help cancer cells grow and retain their DNA/RNA and proteomic signatures, providing researchers with a tool to expand and study cancer cell types found in tumors of the blood and organ systems of all mammals, including humans. Skyline Medical markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. Soluble Biotech is a provider of soluble and stable formulations for proteins including vaccines, antibodies, large and small proteins and protein complexes. For more information, visit the company’s website at www.Predictive-Oncology.com.
NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
